Q1 2009 Earning Report of Sanofi Aventis

Download Q1 2009 Earning Report of Sanofi Aventis

Post on 18-Dec-2014

1.645 views

Category:

Economy & Finance

0 download

Embed Size (px)

DESCRIPTION

 

TRANSCRIPT

<ul><li> 1. Q1 2009 Results April 29, 2009 1 </li> <li> 2. Forward Looking Statements This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include financial and product development projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future events, operations, products and services, and statements regarding future performance. Forward-looking statements are generally identified by the words expects, anticipates, believes, intends, estimates, plans and similar expressions. Although sanofi-aventis management believes that the expectations reflected in such forward- looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of sanofi-aventis, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMEA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives as well as those discussed or identified in the public filings with the SEC and the AMF made by sanofi-aventis, including those listed under Risk Factors and Cautionary Statement Regarding Forward-Looking Statements in sanofi-aventis annual report on Form 20-F for the year ended December 31, 2008. Other than as required by applicable law, sanofi-aventis does not undertake any obligation to update or revise any forward-looking information or statements. 2 </li> <li> 3. Agenda Q1 2009 Achievements Chris Viehbacher, Chief Executive Officer R&amp;D Portfolio Update Marc Cluzel, Senior VP, Research &amp; Development Q1 2009 Market Performance Hanspeter Spek, Executive VP, Pharmaceutical Operations Q1 2009 Financial Performance Jrme Contamine, Executive VP, Chief Financial Officer Q&amp;A Session 3 </li> <li> 4. Q1 2009 Achievements Chris Viehbacher Chief Executive Officer 4 </li> <li> 5. Delivering a Good Start into the Year Q1 2009 Strong underlying sales performance(1) of flagship products and vaccines +3.0% for Pharmaceuticals +9.1% for Vaccines Continued cost management Good growth of adjusted EPS(2) +9.8% at constant exchange rates (CER) +16.8% on a reported basis Transforming initiatives well underway Acquisitions in line with strategy Positive FDA Ad Com for Multaq (dronedarone) (1) Growth is on a constant structure and exchange rates basis 5 (2) Excluding selected items </li> <li> 6. A Diversified Healthcare Company with Several Growth Platforms* Worldwide presence(1) 1,699m, +8.6% Vaccines(2) OTC / OTX(4) Sales: 627m, +9.1% Sales: 762m, +1.3% Sales: 378m, +9.9% Sales: 254m, -8.7% (non-consolidated) Sales: 747m, +27.1% Animal Generics Health(3) Sales: 534m, +8.3% Sales: 93m, +18.3% Sales: $684m, +2.0% (non-consolidated) Worldwide presence(1) 507m, +6.1% (1) Worldwide presence for Plavix/Iscover and Aprovel/Avapro /Karvea includes sales consolidated by sanofi-aventis and BMS (2) Sanofi Pasteur MSD is a 50/50 joint venture with Merck (3) Merial is a 50/50 joint venture with Merck 6 (4) Including the acquisition of Symbion * Sales figures correspond to Q1 2009 sales and growth is at constant exchange rate </li> <li> 7. Guidance for FY 2009 Reiterated Adjusted EPS excluding In 2009, sanofi-aventis expects selected items () growth of adjusted EPS excluding selected items(1) 6.10 of at least 7% 6.00 5.90 At least at constant exchange rates(2), 5.80 +7% 5.70 barring major adverse events 5.60 5.50 5.40 5.30 5.49 5.20 5.10 5.00 2008 2009 (1) FY 2008 adjusted EPS excluding selected items: 5.49 7 (2) Based on actual 2008 average exchange rates for all currencies </li> <li> 8. Rolling-out our Three-Pronged Strategy Adapt Increase Pursue our company innovation external growth to future in R&amp;D opportunities challenges Transforming Program to ensure sustainable, profitable growth and improved risk profile 8 </li> <li> 9. Important Milestones Reached in R&amp;D R&amp;D PORTFOLIO REVIEW BiPar acquisition Thorough and Fulfilling a clear illustrating strong rigorous process unmet patient commitment to need in AF Moving high priority oncology projects forward Creating value for payors Novel tumor- Discontinuing selective approach 4 Phase II and Positive FDA Ad 4 Phase III projects Com on March 18 BSI-201, potential first-in-class Freeing up Potential EMEA compound in resources for decision and U.S. Phase II for TNBC(1) external R&amp;D launch in Q3 2009 New data at ASCO 9 (1) Triple Negative Breast Cancer </li> <li> 10. Three Bolt-on Acquisitions to Strengthen our Growth Platforms 2008 Sales: ~153m 2008 Sales: ~26m 2008 Sales: ~736m #1 generic company A leading generic Leader in branded in Brazil company in Mexico generics in CEE, Turkey and Russia Portfolio of 127 Portfolio of &gt; 50 generic products active ingredients Portfolio of more than 400 products Leadership reinforced in emerging markets Additional stream of sales growth complementing our branded business Improving access to medicines for a wider population Our priority is to expand search for licensing or acquisition deals maintaining a disciplined approach 10 </li> <li> 11. Key Achievements to date &amp; Next Milestones Good Q1 Results - On track to deliver FY 2009 guidance Appointment of new Chief Financial Officer New organization set by Chief Strategic Officer New external R&amp;D deals (eg. BiPar) Disciplined investments in Generics regional growth platforms Completion of R&amp;D pipeline review FDA decision for Multaq (dronedarone) expected in Q2 2009 Emerging Markets Thematic Investor Seminar in Paris on July 2 Q2 Results and Roadmap for Transforming Program in July 29 11 </li> <li> 12. R&amp;D Portfolio Update Marc Cluzel Senior VP, Research &amp; Development 12 </li> <li> 13. R&amp;D Transformation Process is Ongoing Portfolio 1 Prioritization Conduct a detailed objective review of our R&amp;D pipeline Decision 2 Redefine investment decision making process Making 3 Reallocate resources to external R&amp;D partnerships Partnerships 4 Strategy Focus R&amp;D strategy on key technologies and disease areas 5 Organization Implement new R&amp;D organization to encourage innovation 13 </li> <li> 14. Rigorous and Thorough Portfolio Review Complete portfolio review covering Research &amp; Development Multidimensional views aimed at understanding the unique value proposition for each compound Portfolio evaluated across 4 key dimensions: Extent of Overall value Technical &amp; Degree of patient need / Return on commercial innovation addressed investment risk Engaged cross-functional internal expertise while leveraging neutral external party to run the process Going forward, a complete R&amp;D pipeline review will be conducted regularly by newly-created Portfolio Management Group 14 </li> <li>...</li></ul>

Recommended

View more >